Ramesh Agarwal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ramesh Agarwal has a total of 416 co-authors. Here are the top co-authors by number of shared publications:
- Mari Jeeva Sankar
Division of Neonatology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India
27 shared publications Anu Thukral
Division of Neonatology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India
17 shared publicationsVinod K. Paul
Department of Pediatrics, All India Institute of Medical Sciences (AIIMS), New Delhi, India
15 shared publications- Anu Thukral
Division of Neonatology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India
14 shared publications Ashok K. Deorari
Division of Neonatology, Department of Pediatrics, All India Institute of Medical Sciences (AIIMS), New Delhi, India
12 shared publications- Ankit Verma
Division of Neonatology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India
11 shared publications
Latest Publications
- Open Access
- 21 August 2026
- Published by Elsevier in SSRN Electronic Journal
Discovery and Validation of Serum Metabolic Signature of Neonatal Sepsis
A more accurate diagnostic biosignature is crucial for neonatal sepsis. In this report, we identified a serum metabolite signature for diagnosing neonatal sepsis cases using mass spectrometry-based profiling of serum samples from two discovery cohorts (set-I/-II: n=71/269) of sepsis patients (culture positive/negative: CP/CN) and controls (no-sepsis: NS or healthy controls: HC). This signature was validated in both cross-sectional (n=60) and follow-up cohorts (n=100). The six-metabolite signature, which includes 1,5-anhydro-D-sorbitol, lactic acid, malic acid, myo-inositol, phenylalanine, and lysine, can distinguish CP and CN sepsis cases from HC. The deregulated serum metabolites returned to HC levels in neonates after completing antibiotic treatment. Additionally, a metabolic signature of PE (20:4(5Z,8Z,11Z,14Z)/0:0), 12-amino-dodecanoic acid, and 1,5-anhydro-D-sorbitol identified from a validation set-II (n=100) using LC-MS could differentiate CP and CN groups from NS groups. Translating this serum metabolite signature into a simple, deployable blood test for neonatal sepsis could enable faster and more accurate decision-making.
- 21 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessDiscovery and Validation of Serum Metabolic Signature of Neonatal Sepsis
A more accurate diagnostic biosignature is crucial for neonatal sepsis. In this report, we identified a serum metabolite signature for diagnosing neonatal sepsis cases using mass spectrometry-based profiling of serum samples from two discovery cohorts (set-I/-II: n=71/269) of sepsis patients (culture positive/negative: CP/CN) and controls (no-sepsis: NS or healthy controls: HC). This signature was validated in both cross-sectional (n=60) and follow-up cohorts (n=100). The six-metabolite signature, which includes 1,5-anhydro-D-sorbitol, lactic acid, malic acid, myo-inositol, phenylalanine, and lysine, can distinguish CP and CN sepsis cases from HC. The deregulated serum metabolites returned to HC levels in neonates after completing antibiotic treatment. Additionally, a metabolic signature of PE (20:4(5Z,8Z,11Z,14Z)/0:0), 12-amino-dodecanoic acid, and 1,5-anhydro-D-sorbitol identified from a validation set-II (n=100) using LC-MS could differentiate CP and CN groups from NS groups. Translating this serum metabolite signature into a simple, deployable blood test for neonatal sepsis could enable faster and more accurate decision-making.
- Open Access
- 13 May 2026
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 23 (5) , e1005077
Contribution of nosocomial transmission to Klebsiella pneumoniae neonatal sepsis in Africa and South Asia: An observational study of infection clusters inferred from pathogen genomics and temporal data
Background: Klebsiella pneumoniae is the leading cause of sepsis among neonates in low- and middle-income countries (LMICs) in Africa and Asia, contributing substantially to the overall burden of antimicrobial-resistant infections and mortality among neonates globally. Pathogen sequencing has been used to investigate case clusters and confirm nosocomial transmission in a small number of neonatal units. Here we utilise pathogen sequence data to estimate the fraction of K. pneumoniae neonatal sepsis attributable to nosocomial transmission in African and South Asian countries. Methods and findings: We estimated the proportion of invasive K. pneumoniae disease involved in nosocomial transmission clusters in a given neonatal unit, using single-linkage clustering based on pairwise temporal and genetic distances estimated from bacterial whole-genome sequences aggregated from 10 contributing studies. Analysing 1,523 K. pneumoniae isolates from 27 units in 13 countries in Africa and South Asia between 2013 and 2023, we inferred 156 nosocomial transmission clusters, ranging from 2 to 188 neonates each (83 of the clusters comprised ≥3 cases). Overall, we estimated that 1,035 neonatal infections (68.0%) were part of nosocomial transmission clusters. Excluding the first infection in each cluster as a potential index case, we estimate at least 879 (57.7%) infections were acquired via nosocomial transmission. Sensitivity analyses showed that results were robust to the choice of genetic distance estimation methods and thresholds used to define clusters, and cluster estimates were stable over temporal distance thresholds ranging from 2 to 8 weeks. Isolates were mostly extended-spectrum beta-lactamase (ESBL) producers (90.9%) and included 172 multi-locus sequence types (STs). Fourteen STs, including several globally recognised multidrug-resistant lineages, were associated with transmission clusters at multiple units, and these were collectively responsible for two-thirds of all infections. Carriage of carbapenemase genes (adjusted odds ratio, aOR = 2.08 [95% confidence interval, CI: 1.04, 4.14]; p = 0.04) and ESBL genes (aOR = 2.48 [95% CI: 1.26, 4.90]; p = 0.006) were significantly positively associated with transmission in a logistic regression model with site as a covariate. Limitations of this study include the lack of sufficient clinical data to allow high-resolution investigation of transmission dynamics and lack of facility-level data to investigate contributors to the observed differences in transmission burden across sites. Conclusions: Nosocomial transmission contributes to a substantial proportion of K. pneumoniae sepsis in neonatal care units in Africa and South Asia. Reducing transmission within these settings through improved infection prevention and control and other measures could substantially reduce the neonatal sepsis burden. A high burden of transmission clusters is associated with the same drug-resistant lineages that are recognised as high-risk clones associated with hospital outbreaks in high-income countries, indicating global connectivity of the antimicrobial-resistant pathogen population.
- 13 May 2026
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 23 (5) , e1005077
Open AccessContribution of nosocomial transmission to Klebsiella pneumoniae neonatal sepsis in Africa and South Asia: An observational study of infection clusters inferred from pathogen genomics and temporal data
Background: Klebsiella pneumoniae is the leading cause of sepsis among neonates in low- and middle-income countries (LMICs) in Africa and Asia, contributing substantially to the overall burden of antimicrobial-resistant infections and mortality among neonates globally. Pathogen sequencing has been used to investigate case clusters and confirm nosocomial transmission in a small number of neonatal units. Here we utilise pathogen sequence data to estimate the fraction of K. pneumoniae neonatal sepsis attributable to nosocomial transmission in African and South Asian countries. Methods and findings: We estimated the proportion of invasive K. pneumoniae disease involved in nosocomial transmission clusters in a given neonatal unit, using single-linkage clustering based on pairwise temporal and genetic distances estimated from bacterial whole-genome sequences aggregated from 10 contributing studies. Analysing 1,523 K. pneumoniae isolates from 27 units in 13 countries in Africa and South Asia between 2013 and 2023, we inferred 156 nosocomial transmission clusters, ranging from 2 to 188 neonates each (83 of the clusters comprised ≥3 cases). Overall, we estimated that 1,035 neonatal infections (68.0%) were part of nosocomial transmission clusters. Excluding the first infection in each cluster as a potential index case, we estimate at least 879 (57.7%) infections were acquired via nosocomial transmission. Sensitivity analyses showed that results were robust to the choice of genetic distance estimation methods and thresholds used to define clusters, and cluster estimates were stable over temporal distance thresholds ranging from 2 to 8 weeks. Isolates were mostly extended-spectrum beta-lactamase (ESBL) producers (90.9%) and included 172 multi-locus sequence types (STs). Fourteen STs, including several globally recognised multidrug-resistant lineages, were associated with transmission clusters at multiple units, and these were collectively responsible for two-thirds of all infections. Carriage of carbapenemase genes (adjusted odds ratio, aOR = 2.08 [95% confidence interval, CI: 1.04, 4.14]; p = 0.04) and ESBL genes (aOR = 2.48 [95% CI: 1.26, 4.90]; p = 0.006) were significantly positively associated with transmission in a logistic regression model with site as a covariate. Limitations of this study include the lack of sufficient clinical data to allow high-resolution investigation of transmission dynamics and lack of facility-level data to investigate contributors to the observed differences in transmission burden across sites. Conclusions: Nosocomial transmission contributes to a substantial proportion of K. pneumoniae sepsis in neonatal care units in Africa and South Asia. Reducing transmission within these settings through improved infection prevention and control and other measures could substantially reduce the neonatal sepsis burden. A high burden of transmission clusters is associated with the same drug-resistant lineages that are recognised as high-risk clones associated with hospital outbreaks in high-income countries, indicating global connectivity of the antimicrobial-resistant pathogen population.
- 20 January 2026
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 185 (2) , 91
Visual assessment of bilirubin and transcutaneous bilirubinometry in detecting rebound hyperbilirubinemia requiring phototherapy re-initiation in neonates: a prospective diagnostic accuracy study
To evaluate the diagnostic performance of and the potential reduction in blood sampling by (a) visual assessment (VA) for jaundice and (b) transcutaneous bilirubinometry (TcB) at 12–24 h after stopping phototherapy in detecting rebound hyperbilirubinemia requiring re-initiation of phototherapy in neonates born at ≥ 35 weeks’ gestation. This prospective observational study was conducted at a tertiary neonatal unit in India. Eligible neonates underwent VA using Modified Kramer’s method by a neonatal fellow with > 3 years of pediatrics training, TcB using Dräger JM-105™, and total serum bilirubin (TSB) by point-of-care spectrophotometry (One Beam; Ginevri, Italy) at either 12 h (neonates with hemolytic jaundice) or 24 h (neonates with non-hemolytic jaundice) after phototherapy cessation. Outcomes included sensitivity, specificity, likelihood ratios, and reduction in TSB sampling. Among 160 enrolled neonates (gestation: 36 ± 3 weeks; birthweight: 2743 ± 483 g; 35 [21.9%] with hemolytic jaundice), rebound hyperbilirubinemia occurred in 8 (5%). Sensitivity was 100% for both VA and TcB, with VA demonstrating higher specificity (88.2% vs. 71.7%). Positive predictive values were low (VA: 30.8%; TcB: 15.7%), while negative predictive values were 100% for both. Positive likelihood ratios for VA and TcB were 8.4 and 3.5, respectively. VA and TcB could have reduced TSB sampling in 134 (83.8%; 95%CI 77.0–88.7) and 109 (68.1%; 95%CI 60.4–70.9) neonates, respectively. Conclusions: Given their excellent sensitivity and negative predictive values, VA and TcB can enable ruling out rebound hyperbilirubinemia after stopping phototherapy. Using them as primary screening tools can significantly reduce the need for blood sampling to detect rebound hyperbilirubinemia. What is Known: • Rebound hyperbilirubinemia requiring re-initiation of phototherapy occurs in a subset of neonates with pathological hyperbilirubinemia. • While visual assessment (VA) and transcutaneous bilirubinometry (TcB) are non-invasive methods for monitoring jaundice, their role in identifying rebound hyperbilirubinemia remains unclear. What is New: • This study shows excellent sensitivity and negative predictive values of VA and TcB for detecting rebound hyperbilirubinemia. • The results suggest the potential of these two non-invasive methods to decrease blood sampling for serum bilirubin levels, making them valuable tools particularly in resource-constrained settings.
- 20 January 2026
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 185 (2) , 91
Visual assessment of bilirubin and transcutaneous bilirubinometry in detecting rebound hyperbilirubinemia requiring phototherapy re-initiation in neonates: a prospective diagnostic accuracy study
To evaluate the diagnostic performance of and the potential reduction in blood sampling by (a) visual assessment (VA) for jaundice and (b) transcutaneous bilirubinometry (TcB) at 12–24 h after stopping phototherapy in detecting rebound hyperbilirubinemia requiring re-initiation of phototherapy in neonates born at ≥ 35 weeks’ gestation. This prospective observational study was conducted at a tertiary neonatal unit in India. Eligible neonates underwent VA using Modified Kramer’s method by a neonatal fellow with > 3 years of pediatrics training, TcB using Dräger JM-105™, and total serum bilirubin (TSB) by point-of-care spectrophotometry (One Beam; Ginevri, Italy) at either 12 h (neonates with hemolytic jaundice) or 24 h (neonates with non-hemolytic jaundice) after phototherapy cessation. Outcomes included sensitivity, specificity, likelihood ratios, and reduction in TSB sampling. Among 160 enrolled neonates (gestation: 36 ± 3 weeks; birthweight: 2743 ± 483 g; 35 [21.9%] with hemolytic jaundice), rebound hyperbilirubinemia occurred in 8 (5%). Sensitivity was 100% for both VA and TcB, with VA demonstrating higher specificity (88.2% vs. 71.7%). Positive predictive values were low (VA: 30.8%; TcB: 15.7%), while negative predictive values were 100% for both. Positive likelihood ratios for VA and TcB were 8.4 and 3.5, respectively. VA and TcB could have reduced TSB sampling in 134 (83.8%; 95%CI 77.0–88.7) and 109 (68.1%; 95%CI 60.4–70.9) neonates, respectively. Conclusions: Given their excellent sensitivity and negative predictive values, VA and TcB can enable ruling out rebound hyperbilirubinemia after stopping phototherapy. Using them as primary screening tools can significantly reduce the need for blood sampling to detect rebound hyperbilirubinemia. What is Known: • Rebound hyperbilirubinemia requiring re-initiation of phototherapy occurs in a subset of neonates with pathological hyperbilirubinemia. • While visual assessment (VA) and transcutaneous bilirubinometry (TcB) are non-invasive methods for monitoring jaundice, their role in identifying rebound hyperbilirubinemia remains unclear. What is New: • This study shows excellent sensitivity and negative predictive values of VA and TcB for detecting rebound hyperbilirubinemia. • The results suggest the potential of these two non-invasive methods to decrease blood sampling for serum bilirubin levels, making them valuable tools particularly in resource-constrained settings.
- Open Access
- 10 December 2025
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 93 (1) , 85
Neutropenia, Thrombocytopenia and Cholestasis in Infants with Rhesus Hemolytic Disease
- 10 December 2025
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 93 (1) , 85
Open AccessNeutropenia, Thrombocytopenia and Cholestasis in Infants with Rhesus Hemolytic Disease
- 20 November 2025
- Published by Elsevier in Seminars in Fetal and Neonatal Medicine
- Vol. 31 (1) , 101687
Artificial intelligence in neonatal sepsis: Scope, challenges, and potential solutions!
- 20 November 2025
- Published by Elsevier in Seminars in Fetal and Neonatal Medicine
- Vol. 31 (1) , 101687
Artificial intelligence in neonatal sepsis: Scope, challenges, and potential solutions!
- 25 September 2025
- Published by Wiley in Transfusion
- Vol. 65 (11) , 2159-2167
Hematological and iron status in infants with Rh hemolytic disease: A prospective cohort study
Background: Infants with Rh hemolytic disease may have iron overload given the ongoing hemolysis. In these infants, iron supplementation may be unnecessary or potentially even harmful. However, there is a paucity of literature to make evidence‐based recommendations. Methods: All neonates with Rh isoimmunization and evidence of fetal anemia were eligible for inclusion in this cohort study. Primary outcomes were serum ferritin and hemoglobin at birth, 3, 6, 9, and 12 months. Additional outcomes were the requirement of top‐up transfusion and iron therapy during infancy. Iron supplementation was given only if ferritin was n = 46), six‐ ( n = 36), nine‐ ( n = 38), and 12‐months ( n = 35) were 846 [626, 1433], 695 [263, 1041], 219 [105, 601], 122 [42, 242], and 77 [42, 168], respectively. Concomitant hemoglobin (g/ dL ) values were 14.3, 9.4, 10.9, 10.9, and 10.7, respectively. Serum ferritin was above age‐specific cut‐off in 53/56 (95%) infants at birth and remained elevated in 16/35 (46%) at 12 months. Top‐up transfusion was required in 26/47 infants (55%). Iron supplementation was started in 14/46 infants (30%). Ferritin and top‐up transfusion requirements were significantly higher in infants treated with IUT. Discussion: Infants with Rh isoimmunization demonstrate hyperferritinemia at birth, which can persist till 12 months, particularly in IUT‐treated infants. Routine iron supplementation should be deferred in IUT‐treated infants until 12 months.
- 25 September 2025
- Published by Wiley in Transfusion
- Vol. 65 (11) , 2159-2167
Hematological and iron status in infants with Rh hemolytic disease: A prospective cohort study
Background: Infants with Rh hemolytic disease may have iron overload given the ongoing hemolysis. In these infants, iron supplementation may be unnecessary or potentially even harmful. However, there is a paucity of literature to make evidence‐based recommendations. Methods: All neonates with Rh isoimmunization and evidence of fetal anemia were eligible for inclusion in this cohort study. Primary outcomes were serum ferritin and hemoglobin at birth, 3, 6, 9, and 12 months. Additional outcomes were the requirement of top‐up transfusion and iron therapy during infancy. Iron supplementation was given only if ferritin was n = 46), six‐ ( n = 36), nine‐ ( n = 38), and 12‐months ( n = 35) were 846 [626, 1433], 695 [263, 1041], 219 [105, 601], 122 [42, 242], and 77 [42, 168], respectively. Concomitant hemoglobin (g/ dL ) values were 14.3, 9.4, 10.9, 10.9, and 10.7, respectively. Serum ferritin was above age‐specific cut‐off in 53/56 (95%) infants at birth and remained elevated in 16/35 (46%) at 12 months. Top‐up transfusion was required in 26/47 infants (55%). Iron supplementation was started in 14/46 infants (30%). Ferritin and top‐up transfusion requirements were significantly higher in infants treated with IUT. Discussion: Infants with Rh isoimmunization demonstrate hyperferritinemia at birth, which can persist till 12 months, particularly in IUT‐treated infants. Routine iron supplementation should be deferred in IUT‐treated infants until 12 months.
- 12 August 2025
- Published by Springer Nature in Indian Pediatrics
- Vol. 62 (10) , 783-784
Are Nasal CPAP Interfaces Optimal for Indian Neonates? A Call for Anthropometry-Based Design
- 12 August 2025
- Published by Springer Nature in Indian Pediatrics
- Vol. 62 (10) , 783-784
Are Nasal CPAP Interfaces Optimal for Indian Neonates? A Call for Anthropometry-Based Design
- 8 August 2025
- Published by Springer Nature in Indian Pediatrics
- Vol. 62 (11) , 802-808
Feasibility and Safety of Percutaneous Device Closure of Patent Ductus Arteriosus in Preterm Neonates: Experience From a Single Center in Northern India
To report the feasibility and safety of percutaneous device closure of patent ductus arteriosus (PDA) in preterm neonates from a tertiary center in Northern India. A retrospective chart review of the clinical profile, nature of device used, and outcomes of inborn preterm neonates who underwent percutaneous device closure of PDA was conducted. The intervention was performed by experienced pediatric cardiologists using a transvenous approach under fluoroscopic guidance. Ten neonates with median (Q1, Q3) gestation of 29 (27, 30) weeks underwent device (Piccolo device) closure at a median (Q1, Q3) age of 37 (27, 41) days. At the time of procedure, the median (Q1, Q3) weight of the infants was 1270 (1120, 1890) g and the median (Q1, Q3) PDA diameter was 3.0 (2.3, 3.0) mm. Successful PDA closure was achieved in nine neonates; six showed clinical improvement. No procedure-related death was observed. Percutaneous device closure of PDA in preterm neonates is safe and feasible.
- 8 August 2025
- Published by Springer Nature in Indian Pediatrics
- Vol. 62 (11) , 802-808
Feasibility and Safety of Percutaneous Device Closure of Patent Ductus Arteriosus in Preterm Neonates: Experience From a Single Center in Northern India
To report the feasibility and safety of percutaneous device closure of patent ductus arteriosus (PDA) in preterm neonates from a tertiary center in Northern India. A retrospective chart review of the clinical profile, nature of device used, and outcomes of inborn preterm neonates who underwent percutaneous device closure of PDA was conducted. The intervention was performed by experienced pediatric cardiologists using a transvenous approach under fluoroscopic guidance. Ten neonates with median (Q1, Q3) gestation of 29 (27, 30) weeks underwent device (Piccolo device) closure at a median (Q1, Q3) age of 37 (27, 41) days. At the time of procedure, the median (Q1, Q3) weight of the infants was 1270 (1120, 1890) g and the median (Q1, Q3) PDA diameter was 3.0 (2.3, 3.0) mm. Successful PDA closure was achieved in nine neonates; six showed clinical improvement. No procedure-related death was observed. Percutaneous device closure of PDA in preterm neonates is safe and feasible.